Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Journal of Clinical Oncology(2024)10.1200/jco.23.01680Source: DataRank Database

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) is a research paper published in Journal of Clinical Oncology (2024). On theSindex it has a DataRank of 0.944. It has been cited 25 times, with 21 citing works in its 1-hop citation network.

N/A

0.944DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access25 citations · 21 citing works in its network

Download PDF

Cite:

Linked data & code

gen nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01150045

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 8.57)OA: greenTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 52%Citation Network 48%

Base Score Contribution

0.489

From this paper's citation signal

Citation Network Contribution

0.455

From 13 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 21 citers.

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
New England Journal of Medicine202561 citations25 referencesContributes 0.165
Adjuvant Aspirin Treatment in PIK3CA -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Clinical Cancer Research202516 citations23 referencesContributes 0.123
Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis
PLoS ONE202518 citations47 referencesContributes 0.063
Tailored COX-2 Inhibition for Precision Adjuvant Therapy of Localized Metastatic Colon Cancer
JAMA Oncology20251 citations15 referencesContributes 0.046
MED: Multiplexed, Entropy-Driven Catalysis, Single-Nucleotide-Resolved ctDNA Detection
Analytical Chemistry20252 citations39 referencesContributes 0.028

Authors (22)

Tyler S. Twombly,Chao Ma ORCID,Qian Shi ORCID,Koichiro Haruki ORCID,Kenji Fujiyoshi ORCID

Live enrichment

PubMed:38889377 PMC:PMC11392453 OpenAlex:https://openalex.org/W4399765099

NCI NIH HHS

Grant: U10 CA180868

NCI NIH HHS

Grant: UG1 CA233234

NCI NIH HHS

Grant: UG1 CA233180

NCI NIH HHS

Grant: UG1 CA233339

NCI NIH HHS

Grant: U10 CA180882

NCI NIH HHS

Grant: U10 CA180888

NCI NIH HHS

Grant: U10 CA180794

NCI NIH HHS

Grant: U10 CA180820

NCI NIH HHS

Grant: U24 CA196171

NCI NIH HHS

Grant: UG1 CA189830

NCI NIH HHS

Grant: UG1 CA233290

NCI NIH HHS

Grant: UG1 CA189954

NCI NIH HHS

Grant: UG1 CA233163

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: R01 CA169141

NCI NIH HHS

Grant: U10 CA180821

NCI NIH HHS

Grant: U10 CA180863

NCI NIH HHS

Grant: UG1 CA233337

FWCI

8.57

Citation Percentile

1.0%

Citation Trend

2025

2026

green

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11392453/pdf/nihms-2016725.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11392453

journalhttps://doi.org/10.1200/jco.23.01680

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38889377

Fields of Study

Inflammatory mediators and NSAID effectsColorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCelecoxibChemotherapy, AdjuvantClass I Phosphatidylinositol 3-KinasesColonic NeoplasmsCyclooxygenase 2 InhibitorsDisease-Free SurvivalMutationNeoplasm StagingProspective Studies

MeSH Terms

CelecoxibAdultAgedAntineoplastic Combined Chemotherapy ProtocolsColonic NeoplasmsFemaleHumansMaleMiddle AgedMutationNeoplasm StagingProspective StudiesChemotherapy, AdjuvantDisease-Free SurvivalCyclooxygenase 2 InhibitorsClass I Phosphatidylinositol 3-Kinases

Keywords

MedicineInternal medicineHazard ratioOncologyColorectal cancerClinical endpointCancerCelecoxibProportional hazards modelRandomized controlled trialConfidence interval

Sustainable Development Goals

SDG 0: Good health and well-being